JPMorgan, Jefferies, Citi and Wells Fargo acted as joint book running managers for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Beam Therapeutics announces ‘positive’ data from study of BEAM-302
- Beam Therapeutics price target raised to $25 from $24 at Scotiabank
- Cautious Optimism for Beam Therapeutics Amid Upcoming Milestones and Financial Considerations
- Beam Therapeutics: Promising Pipeline and Strong Financial Position Justify Buy Rating
- Biotech Alert: Searches spiking for these stocks today
Questions or Comments about the article? Write to editor@tipranks.com